Overview

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
0
Participant gender:
Female
Summary
Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Raloxifene Hydrochloride
Teriparatide
Criteria
Inclusion Criteria:

- Postmenopausal women aged at least 50 years

- A previous clinical diagnosis of osteoporosis

- At high risk for fracture

- Current therapy for at least 18 months prior to study entry with either raloxifene HCl
or alendronate Na

Exclusion Criteria:

- History of metabolic bone disease other than osteoporosis

- History of malignant neoplasm within the last 5 years except for superficial basal
cell carcinoma or squamous cell carcinoma